GlassScriptPhysician profile
Adrian Mclemore
NPI 1902257124
$925.37
in general payments reported to CMS, 2019-2025
13 companies · $61.34 in 2025
The $61.34 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $272 · 2022: $271 · 2023: $130 · 2024: $191 · 2025: $61.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $323.51 | 2021-2024 | Mounjaro, Zepbound, Emgality |
| Abbott Laboratories | $176.03 | 2021-2024 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $69.64 | 2022 | |
| Novo Nordisk INC | $69.63 | 2021-2024 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $69.21 | 2021-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $62.39 | 2021-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $46.09 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.18 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.85 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $14.12 | 2025 | Arexvy, Shingrix |
| Idorsia Pharmaceuticals US INC | $13.60 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $13.52 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Mclemore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.